Prostate cancer: Natural history and surgical treatment of localised disease

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; EUROPE; HUMAN; INCIDENCE; LAPAROSCOPY; MALE; METHODOLOGY; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; SURVIVAL;

EUROPE; HUMANS; INCIDENCE; LAPAROSCOPY; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0035496613     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80014-9     Document Type: Article

References (56)

1. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977, 20: 680-688.
2. Sakr WA, Billis A, Ekman P, Wilt T, Bostwick DG. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Nephrol Suppl 2000, 205: 11-18.
3. Clark LC, Dalkin B, Krongrad A, Combs JGF, Turnbull BW, Slate EH et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. BJU 1998, 81: 730-734.
4. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90: 440-446.
5. Moller Jensen O, Estève J, Moller H, Renard H. Cancer in the European Community and its members states. Eur J Cancer 1990, 26: 1167-1256.
6. Greenlee RT, Hill-Harmon MB, Thun M. Cancer Statistics, 2001. CA Cancer J Clin 2001, 51: 15-36.
7. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC et al. Cancer Surveillance Series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999, 91: 1017-1024.
8. Stanford JL, Stephenson RA, Coyle LM, Cehran J, Correra R, Eley JW et al. Prostate Cancer Trends 1973-1995, SEER Program National Cancer Institute. National Cancer Institute Monograph 1998. (http://www.seer.img.nci.nih.gov) 1998.
9. Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999, 161: 1192-1198.
10. Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 1995, 46 (3 Suppl A): 47-55.
11. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000, 355(9217): 1788-1789.
12. Visser O, Coebergh JWW, Schouten LJ, van Dijck JAAM (Eds.). Incidence of Cancer in the Netherlands 1997. Vereniging van Integrale Kankercentra, Utrecht, 2001.
13. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994, 344(8937): 1594-8.
14. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. AMA 1995, 273: 289-94.
15. Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. British Medical Journal 1995, 311(7016): 1340-3.
16. Ohori M, Wheeler TM, Dunn JK, Stamey TA. Scardino PT. The pathological features and prognosis of prostate cancers detectable with current diagnostic tests. J Urol 1994, 152: 1714-1720.
17. Montic JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 1994, 43(6): 892-999.
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271(5): 368-74.
19. Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000, 163: 806-812.
20. Davidson PJT, Hop W, Kurth KH, Fossa SD, Waehre H, Schröder FH et al. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 to 4,N1 to 3,Mo,D1). J Urol 1995, 154: 2118-2122.
21. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994, 330: 242-248.
22. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995, 274(8): 626-631.
23. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998, 280(11): 975-980.
24. Van den Ouden D, Hop WCJ, Kranse R, Schröder FH. Tumor control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997, 79: 203-211.
25. Narain V, Bianco F, Heath M, Grignon DJ, Sakr WA, Pontes JE et al. How accurately does biopsy information determine outcome? Chapter 12. In: Kurth KH, Mickisch GH, Schröder FH, editors. Renal, Bladder, Prostate and Testicular Cancer. An Update. The proceedings of the VI Congress on Progress and Controversies in Oncological Urology (PACIOU VI), Rotterdam, The Netherlands, October 2000. New York, London: The Parthenon Publishing Group; 2001. pp. 113-120 (ISBN 1-8421-067-1).
26. Catalona WJ. Patient selection for, results of, and impact on tumor resection of potency-sparing radical prostatectomy. Urol Clin North Am 1990, 17(4): 819-26.
27. Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001, 32: 81-88.
28. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Urology 1993, 41: 207-216.
29. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997, 277: 1445-1451.
30. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Urol Clin North Am 1993, 20: 705-711.
31. Albertsen PC, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM et al. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 2000, 163: 1138-1143.
32. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000, 56: 988-93.
33. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA et al. 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998, 159(6): 2041-2046.
34. Walsh PC. Anatomic radical retropubic prostatectomy. Chapter 86. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ (Eds.), Campbell's Urology. Seventh Edition. W.B. Saunders Company, Philadelphia, 1988, pp. 2565-2588 (ISBN 0-7216-4461-9).
35. Young HH. The early diagnosis and radical cure of carcinoma of the prostate - a study of 40 cases and presentation of a radical operation was carried out in 4 cases. Johns Hopkins Hospital Bulletin 1905, 16: 315.
36. Belt E. Radical perineal prostatectomy in early carcinoma of the prostate. J Urol 1942, 48: 287.
37. Weldon VE, Tavel FR. Potency-sparing radical perineal prostatectomy: anatomy, surgical technique and initial results. J Urol 1988, 140: 559-562.
38. Guillonneau B, Vallancien G. Laparoscopic radical prostatectomy: the Montsouris technique. J Urol 2000, 163: 1643-1649.
39. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am 1997, 24: 395-406.
40. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000, 163: 1802-1807.
41. Fowler FJ Jr., Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993, 42: 622-9.
42. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001, 19(6): 1612-1928.
43. Boccon-Gibod L, Ravery V, Vordos D, Toublanc M, Delmas V, Boccon-Gibod L. Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. J Urol 1998, 160: 1383-1385.
44. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995, 153: 1565-9.
45. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Tomaszewski JE et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. Chapter 15. In: Kurth KH MG, Schröder FH (Ed.), Renal, bladder, prostate and testicular cancer. An Update. Proceedings of the VI congress of Progress and Controversies in Oncological Urology (PACIOU VI), Rotterdam, October 2000. New York, London: The Parthenon Publishing Group, 2001, pp. 147-157.
46. Whitmore WFJ. Overview: historical and contemporary. In: NCI Monograph, 1988, p 7-11.
47. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 282: 1591.
48. Van den Ouden D, Davidson PJT, Hop W, Schröder FH. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1994, 151: 646-651.
49. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993, 41: 113-120.
50. Jewett HJ, Bridge RW, Gray GF, Shelley WM. The palpable nodule of prostatic cancer. JAMA 1968, 203: 403-406.
51. Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JI. Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol 1994, 151: 1583-1586.
52. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 1997, 349: 906-910.
53. Gerber GS, Thisted RA, Chodak GW, Schröder FH, Frohmuller HG, Scardino PT et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997, 32: 385-390.
54. Scardino PT, Wheeler TM, Kattan MW. Is cure of prostate cancer possible in those for whom it is necessary? Chapter 16. In: Kurth KH, Mickisch GH, Schröder FH (Eds.), Renal, Bladder and Prostate Cancer. An Update. The Proceedings of the V Congress on Progress and Controversies in Oncological Urology (PACIOU V), Rotterdam, October 1998. New York, London: The Parthenon Publishing Group, 1999, pp. 131-136 (ISBN 1-85070-081-8).
55. Litwin MS, Fitzpatrick JM, Fossa SD, Newling DWW. Defining an international research agenda for quality of life in men with prostate cancer. Prostate 1999, 41: 58-67.
56. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994, 152: 1843-1849.